- Home
- JBLU vs IRON Comparison
JBLU vs IRON Comparison
Compare JBLU & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBLU
- IRON
- Stock Information
- Founded
- JBLU 1998
- IRON 2017
- Country
- JBLU United States
- IRON United States
- Employees
- JBLU N/A
- IRON N/A
- Industry
- JBLU Air Freight/Delivery Services
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- JBLU Consumer Discretionary
- IRON Health Care
- Exchange
- JBLU Nasdaq
- IRON Nasdaq
- Market Cap
- JBLU 2.0B
- IRON 2.0B
- IPO Year
- JBLU N/A
- IRON N/A
- Fundamental
- Price
- JBLU $5.08
- IRON $60.76
- Analyst Decision
- JBLU Sell
- IRON Strong Buy
- Analyst Count
- JBLU 11
- IRON 10
- Target Price
- JBLU $5.08
- IRON $97.80
- AVG Volume (30 Days)
- JBLU 18.1M
- IRON 299.1K
- Earning Date
- JBLU 10-28-2025
- IRON 08-07-2025
- Dividend Yield
- JBLU N/A
- IRON N/A
- EPS Growth
- JBLU N/A
- IRON N/A
- EPS
- JBLU N/A
- IRON N/A
- Revenue
- JBLU $9,138,000,000.00
- IRON N/A
- Revenue This Year
- JBLU N/A
- IRON N/A
- Revenue Next Year
- JBLU $7.48
- IRON N/A
- P/E Ratio
- JBLU N/A
- IRON N/A
- Revenue Growth
- JBLU N/A
- IRON N/A
- 52 Week Low
- JBLU $3.34
- IRON $30.82
- 52 Week High
- JBLU $8.31
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- JBLU 52.01
- IRON 56.26
- Support Level
- JBLU $5.16
- IRON $59.74
- Resistance Level
- JBLU $5.73
- IRON $63.51
- Average True Range (ATR)
- JBLU 0.25
- IRON 2.05
- MACD
- JBLU -0.03
- IRON -0.00
- Stochastic Oscillator
- JBLU 21.69
- IRON 44.17
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.